Passage BIO, Inc. 8K

Passage Bio furnished an investor presentation outlining clinical, preclinical, regulatory, and manufacturing updates for its PBFT02 FTD-GRN gene therapy and Huntington’s disease program, along with an updated cash runway outlook through 1Q 2027.

Passage Bio, Inc. furnished an April 2026 corporate presentation (Exhibit 99.2) describing interim clinical, preclinical, regulatory, and manufacturing progress for its gene therapy programs, led by PBFT02 for frontotemporal dementia with GRN mutations (FTD‑GRN), including Phase 1/2 upliFT‑D trial design and biomarker data showing robust, durable increases in CSF progranulin and early signals of reduced brain atrophy and stable plasma NfL versus natural history, a generally tolerable safety profile, FDA Fast Track and Orphan Drug designations, completion of key CMC milestones enabling late‑stage development, expected cash runway through the first quarter of 2027, and advancement of a preclinical Huntington’s disease program targeting MSH3 to reduce CAG repeat somatic instability.

Filing Facts

CIK

1787297

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-045219

Alert Tier

5